Enhanced antitumor activity of realgar mediated by milling it to nanosize

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 745-757

  Tian, Ye ^a   Wang, Xiaobo ^a,b   Xi, Ronggang ^a,b   Pan, Weisan ^a   Jiang, Shuang ^b   Li, Zhao ^a   Zhao, Yu ^c   Gao, Guanghui ^d   Liu, Dan ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b The 210th Hospital of PLA   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d Liaoning Institute for Food and Drug Control   (China)

Author keywords

Biodistribution; Cytotoxicity; High energy ball milling; Pharmacokinetics; Realgar nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC DISULFIDE; NANOPARTICLE; ORGANOARSENIC DERIVATIVE; SULFIDE;

ANIMAL; BIOAVAILABILITY; CELL SURVIVAL; CHINESE MEDICINE; DRUG EFFECTS; FEMALE; HEPG2 CELL LINE; HUMAN; MCF 7 CELL LINE; MOUSE; NANOMEDICINE; PARTICLE SIZE; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HEP G2 CELLS; HUMANS; MCF-7 CELLS; MEDICINE, CHINESE TRADITIONAL; MICE; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SULFIDES;

EID: 84893228567     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S56391     Document Type: Article

References (35)

1. Frankenberger WT. Environmental Chemistry of Arsenic. Boca Raton (FL): CRC; 2002.
2. Wu JZ, Ho PC. Evaluation of the in vitro activity and in vivo bioavail- ability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci. 2006;29(1):35-44.
3. Wu J, Shao Y, Liu J, Chen G, Ho PC. The medicinal use of realgar (As4S4) and its recent development as an anticancer agent. J Ethnopharmacol. 2011;135(3):595-602.
4. Lu DP, Wang Q. Current study of APL treatment in China. Int J Hematol. 2002;76 Suppl 1:316-318.
5. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99(9):3136-3143.
6. Shilin H, Aixia G, Yang X. Clinical study on the treatment of acute promyelocytic leukemia mainly with composite indigo naturalis tablets. Zhonghua Xue Ye Xue Za Zhi. 1995;16(1):26-28.
7. Mao JH, Sun XY, Liu JX, et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2010;107(50):21683-21688.
8. Offergelt J, Roels H, Buchet J, Boeckx M, Lauwerys R. Relation between airborne arsenic trioxide and urinary excretion of inorganic arsenic and its methylated metabolites. Br J Ind Med. 1992;49(6):387-393.
9. Dong JT, Luo XM. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res. 1994;315(1):11-15.
10. Lee TC, Oshimura M, Barrett JC. Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis. 1985;6(10): 1421-1426.
11. Williamson EM, Lorenc A, Booker A, Robinson N. The rise of tra- ditional Chinese medicine and its materia medica: a comparison of frequency and safety of materials and species used in Europe and China. J Ethnopharmacol. 2013;149(2):453-462.
12. Beak DG, Basta NT, Scheckel KG, Traina SJ. Bioaccessibility of arsenic(V) bound to ferrihydrite using a simulated gastrointestinal system. Environ Sci Technol. 2006;40(4):1364-1370.
13. Mainardes RM, Urban MC, Cinto PO, et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets. 2005;6(3):363-371.
14. Bittner B, Mountfield R. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel. 2002;5(1):59-71.
15. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311-330.
16. Baláž P, Fabián M, Pastorek M, Cholujová D, Sedlák J. Mechanochemical preparation and anticancer effect of realgar As4S4 nanoparticles. Mater Lett. 2009;63(17):1542-1544.
17. Baláž P, Dutková E. Mechanochemistry of sulphides. J Therm Anal Calorim. 2007;90(1):85-92.
18. Wang XB, Gao HY, Hou BL, Huang J, Xi RG, Wu LJ. Nanoparticle realgar powders induce apoptosis in u937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res. 2007;30(5): 653-658.
19. Zhan XQ, Guo LW, Fu TM, Yuan HY. A study on preparation and diameter determination of realgar granule of micron or nanometer dimension. J Nanjing Univ Tradit Chin Med. 2003;19(1):24-25.
20. Ning N, Peng Z, Yuan L, Gou B, Zhang T, Wang K. [Realgar nanopar- ticles induce apoptosis and necrosis in leukemia cell lines K562 and HL-60]. Zhongguo Zhong Yao Za Zhi. 2005;30(2):136-140. Chinese.
21. Shen XC, Guo YF, Wei J, Liang H. Preparation and the biological effects of realgar nanoparticles. Twenty-Fifth Chinese Chemical Society Annual Conference Abstract Book. Chinese Chemical Society, Tianjin, People's Republic of China. 2006.
22. Wang J, Loh KP, Wang Z, etal. Fluorescent nanogel of arsenic sulfide nanoclusters. Angew Chem Int Ed Engl. 2009;48(34):6282-6285.
23. Baláž P, Bujňáková Z, Kartachova O, Fabián M, Stalder B. Properties and bioaccessibility of arsenic sulphide nanosuspensions. Mater Lett. 2013;(104):84-86.
24. Wang N, Wang LW, Gou BD, Zhang TL, Wang K. Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells. Cell Biol Int. 2008;32(12):1497-1505.
25. Ye HQ, Gan L, Yang XL, Xu HB. Membrane toxicity accounts for apoptosis induced by realgar nanoparticles in promyelocytic leukemia HL-60 cells. Biol Trace Elem Res. 2005;103(2):117-132.
26. Luo LY, Huang J, Gou BD, Zhang TL, Wang K. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulphide: involvement of serine/threonine protein phosphatases. Leuk Res. 2006;30(11):1399-1405.
27. Wu JZ, Ho PC. Comparing the relative oxidative DNA damage caused by various arsenic species by quantifying urinary levels of 8-hydroxy- 2′-deoxyguanosine with isotope-dilution liquid chromatography/mass spectrometry. Pharm Res. 2009;26(6):1525-1533.
28. Deng Y, Xu H, Huang K, Yang X, Xie C, Wu J. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304. Pharmacol Res. 2001;44(6):513-518.
29. Bode AM, Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol. 2002;42(1):5-24.
30. Xi RG, Huang J, Li D, Wang XB, Wu LJ. Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced apoptosis in U937 cells. Acta Pharmacol Sin. 2008;29(3):355-363.
31. Liu J, Lu Y, Wu Q, Goyer RA, Waalkes MP. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmac Exp Ther. 2008;326(2):363-368.
32. Buchet J, Lauwerys R, Roels H. Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health. 1981;48(2):111-118.
33. Hansen MB, Nielsen SE, Berg K. Re-examination and further develop- ment of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989;119(2):203-210.
34. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47(4): 936-942.
35. Cui X, Kobayashi Y, Hayakawa T, Hirano S. Arsenic speciation in bile and urine following oral and intravenous exposure to inorganic and organic arsenics in rats. Toxicol Sci. 2004;82(2):478-487.